Prurigo nodularis

Prurigo nodularis
Other namesHyde's disease, nodular prurigo
Prurigo nodularis lesions on the legs, arms, and trunk of a patient
Nodular lesions on the lateral surface of a patient's hand
SpecialtyDermatology
SymptomsFirm, symmetrically distributed nodules or papules with paroxysmal intense chronic pruritus
ComplicationsAnxiety, depression, sleep disturbances, secondary bacterial infection
Usual onsetAdulthood or advanced age
DurationChronic, refractory, and prone to recurrence
TypesClassified by lesion count: mild (<20), moderate (20–99), severe (≥100)
CausesThe interaction of three links: primary epidermal barrier defect, type II immune inflammation, and neural structural remodeling.
Risk factorsAdvanced age, female sex, Black ethnicity, diabetes mellitus, peripheral neuropathy, chronic kidney disease
Diagnostic methodMorphology of skin lesions (texture, size), distribution pattern (extensor limbs, butterfly sign)
Differential diagnosisDermatitis, Lichen planus, Bullous pemphigoid, Scabies
PreventionAvoid scratching and friction, intensive gentle moisturization, avoidance of triggers
TreatmentConventional medications, physical therapies, and biologic agents
MedicationCorticosteroids, immunosuppressive drugs, biologic agents
FrequencyGlobal prevalence approximately 0.083%

Prurigo nodularis (PN) is a chronic, inflammatory skin disease characterized by intense pruritus and symmetrically distributed, firm papules or nodules on the skin. The core pathogenesis of PN involves a three-stage model comprising primary epidermal barrier defect, type 2 immune inflammation, and neural structural remodeling.

Clinically, the diagnosis of PN relies on the characteristic morphology of skin lesions, their distinctive anatomical distribution, and the pattern of chronic severe pruritus. Epidemiological data indicate that the global prevalence of PN is approximately 0.083%, predominantly affecting adults and the elderly, with higher incidence rates observed in females and individuals of Black ethnicity.

Treatment of PN follows a multimodal, stepwise approach, ranging from topical corticosteroids and phototherapy to biologic agents targeting the type 2 inflammatory pathway. Because PN is frequently associated with systemic diseases (such as diabetes and renal disease), peripheral neuropathy, and psychiatric comorbidities (anxiety and depression), effective clinical management requires simultaneous addressing of skin lesions, neurological symptoms, and psychosocial factors in order to interrupt the persistent itch-scratch cycle.